Tilia Fiduciary Partners Inc. Decreases Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Tilia Fiduciary Partners Inc. cut its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 7.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 860 shares of the biotechnology company’s stock after selling 70 shares during the period. Tilia Fiduciary Partners Inc.’s holdings in Axon Enterprise were worth $452,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Savant Capital LLC raised its stake in Axon Enterprise by 5.7% in the fourth quarter. Savant Capital LLC now owns 1,080 shares of the biotechnology company’s stock valued at $642,000 after buying an additional 58 shares in the last quarter. Principal Securities Inc. raised its stake in Axon Enterprise by 255.7% in the fourth quarter. Principal Securities Inc. now owns 1,085 shares of the biotechnology company’s stock valued at $645,000 after buying an additional 780 shares in the last quarter. Empowered Funds LLC increased its position in shares of Axon Enterprise by 89.2% during the fourth quarter. Empowered Funds LLC now owns 1,871 shares of the biotechnology company’s stock worth $1,112,000 after purchasing an additional 882 shares in the last quarter. Xponance Inc. increased its position in shares of Axon Enterprise by 3.5% during the fourth quarter. Xponance Inc. now owns 16,469 shares of the biotechnology company’s stock worth $9,788,000 after purchasing an additional 560 shares in the last quarter. Finally, Brighton Jones LLC acquired a new stake in shares of Axon Enterprise during the fourth quarter worth about $480,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Trading Up 0.4%

AXON stock opened at $791.85 on Friday. The company has a market cap of $61.65 billion, a price-to-earnings ratio of 204.61, a PEG ratio of 5.17 and a beta of 1.29. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The business has a fifty day simple moving average of $643.89 and a 200-day simple moving average of $616.49. Axon Enterprise, Inc. has a 52 week low of $278.24 and a 52 week high of $798.16.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same period in the prior year, the firm posted $1.15 EPS. The business’s revenue for the quarter was up 31.3% on a year-over-year basis. On average, equities research analysts expect that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Analyst Ratings Changes

AXON has been the subject of several analyst reports. Barclays upped their price objective on Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a research note on Friday, May 9th. Bank of America upped their target price on Axon Enterprise from $750.00 to $895.00 and gave the company a “buy” rating in a research note on Wednesday. Needham & Company LLC upped their target price on Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. The Goldman Sachs Group upped their target price on Axon Enterprise from $730.00 to $830.00 and gave the company a “buy” rating in a research note on Wednesday, May 14th. Finally, Craig Hallum lowered Axon Enterprise from a “buy” rating to a “cautious” rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $699.55.

Insider Activity at Axon Enterprise

In related news, Director Jeri Williams sold 307 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $552.72, for a total value of $169,685.04. Following the completion of the sale, the director now directly owns 1,627 shares in the company, valued at approximately $899,275.44. This represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brittany Bagley sold 3,400 shares of the stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $700.00, for a total value of $2,380,000.00. Following the completion of the sale, the chief financial officer now owns 131,833 shares of the company’s stock, valued at approximately $92,283,100. This represents a 2.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 43,969 shares of company stock worth $29,909,594. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.